Loading...
XASXOCC
Market cap190mUSD
Dec 27, Last price  
1.28AUD
1D
0.00%
1Q
201.18%
Jan 2017
236.84%
IPO
245.95%
Name

Orthocell Ltd

Chart & Performance

D1W1MN
XASX:OCC chart
P/E
—
P/S
57.72
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
11.28%
Rev. gr., 5y
41.24%
Revenues
5m
+25.27%
524,281691,405790,430666,499529,818619,179945,657719,5231,017,9621,531,7184,243,0695,315,375
Net income
-7m
L+14.93%
-1,323,330-2,182,185-3,742,715-3,784,864-4,177,416-5,757,114-5,852,214-6,151,029-9,037,025-9,106,585-6,248,181-7,180,959
CFO
-7m
L
-290,572-1,753,026-2,767,613-3,321,118-3,555,380-4,644,252-4,180,466-5,256,871-4,633,330-6,261,45614,592,580-6,505,126
Earnings
Feb 21, 2025

Profile

Orthocell Limited, a regenerative medicine company, develops and commercializes cell therapies and biological medical devices for the repair of various bone and soft tissue injuries in Australia. The company offers CelGro, a naturally derived collagen medical device for use in multiple indications to augment the surgical repair of bone, peripheral nerves, tendons, and cartilage; and Ortho-ATI, a cell therapy for treatment of chronic tendon injuries. It also provides Ortho-ACI, an autologous chondrocyte implantation to treat articular cartilage defects in the knee and ankle; Striate+, a resorbable collagen membrane used for guided bone and tissue regeneration in dental application; and Remplir, a collagen scaffold used in peripheral nerve repair. Orthocell Limited was incorporated in 2006 and is headquartered in Murdoch, Australia.
URL
http://www.orthocell.com.au/
IPO date
Aug 12, 2014
Employees
Domiciled in
AU
Incorporated in
AU

Valuation

Title
AUD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑062023‑062022‑062021‑062020‑062019‑062018‑062017‑062016‑062015‑06
Income
Revenues
5,315
25.27%
4,243
177.01%
1,532
50.47%
Cost of revenue
16,996
14,740
13,053
Unusual Expense (Income)
NOPBT
(11,681)
(10,497)
(11,521)
NOPBT Margin
Operating Taxes
(3,051)
(3,162)
(2,144)
Tax Rate
NOPAT
(8,630)
(7,334)
(9,377)
Net income
(7,181)
14.93%
(6,248)
-31.39%
(9,107)
0.77%
Dividends
Dividend yield
Proceeds from repurchase of equity
(123)
1,637
BB yield
0.17%
-2.08%
Debt
Debt current
149
181
120
Long-term debt
1,230
763
775
Deferred revenue
16,071
18,375
20,679
Other long-term liabilities
165
169
107
Net debt
(19,235)
(23,874)
(10,126)
Cash flow
Cash from operating activities
(6,505)
14,593
(6,261)
CAPEX
(927)
(632)
(535)
Cash from investing activities
(942)
(632)
(535)
Cash from financing activities
3,244
(165)
1,490
FCF
(9,585)
10,006
(27,389)
Balance
Cash
20,614
24,818
11,022
Long term investments
Excess cash
20,349
24,606
10,945
Stockholders' equity
4,533
6,149
9,905
Invested Capital
16,926
19,107
21,293
ROIC
ROCE
EV
Common stock shares outstanding
202,008
197,213
194,666
Price
0.36
1.43%
0.35
-13.58%
0.41
-31.36%
Market cap
71,713
3.89%
69,025
-12.45%
78,840
-28.49%
EV
52,478
45,151
68,713
EBITDA
(11,164)
(9,943)
(11,173)
EV/EBITDA
Interest
61
31
Interest/NOPBT